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assumed patients would
not have a chance to
develop appetites for
the substances. This
proved to be a tragic
miscalculation, especially
for the creator of the
hypodermic
needle,
Alexander Wood, whose
wife would become the
first recorded death from
injected opiates.
Heroin was first synthesized
from morphine in 1847 by Dr. Alder
Wright in his search for a nonaddictive alternative to morphine,
and again by Heinrich Dresser, a
Bayer Laboratory chemist, in 18983.
The creators and doctors believed
at the time that heroin, which had
proved to be an excellent painkiller,
was non-addictive. The new
compound was prescribed broadly,
primarily because doctors had little
else to prescribe to ease pain and
provide relief from suffering. By
the beginning of the 20th century,
miracle remedies with morphine,
opium, and heroin as their active
ingredients, under the guise of
benign sounding names such as
Mrs. Winslow’s Soothing Syrup,
were widely used and abused. In
a letter presented to the American
Pharmaceutical Association in
May of 1903, The Committee on
the Acquirement of Drug Habits
asserted that “careful study of data
personally collected from reliable
sources forced the conclusion that
the habitual use of opium and its
various forms [was] increasing and
that this increase [was] confined
to no one class or occupation”
meaning it posed a serious and
wide reaching public health threat 4.
Unfortunately, the address goes on
to assert that the only way by which
the public appetite for narcotics
could be curbed was through the
enactment of stringent laws to act
as significant barriers to accessing
the compounds. It recommended
the termination of narcotics sales

To administer naloxone, pull or pry off the yellow cap on
the adapter, pry off the purple cap off of naloxone and grip
the clear plastic wings on the nasal atomizer, screwing it into
the adapter, then screw the capsule of naloxone into the
barrel of the adapter. Tilt the head back and insert the white
cone into one nostril; spray half of the dose of naloxone
(approximately 1 cc) into one nostril and the other half into
the other1.

T

hese directions are not
for medical professionals,
or even first responders,
but rather the instructions provided
by a short training video produced
by Project DAWN (Deaths Avoided
With Naloxone) an Ohio Health
Department initiative that aims
to teach lay people to administer
the life saving drug in the event
of opioid overdose. Currently,
an estimated 130 Americans die
per day from opioid overdose2.
Across the country, opioids are
presumably responsible for 47,600,
or almost 68%, of the 70,200
drug overdose deaths recorded in
2017, the last year for which CDC
data is available. In Ohio alone,
opioids were responsible for an
average of 46.3 of every 100,000
deaths, placing the state second
for the most opioid deaths per
capita, just behind West Virginia.
These staggering statistics beg the
question: “How did we get here?”

The History of
Opioids in Pain
Treatment
Humankind’s disastrous love
affair with opioids is nothing
new. The story begins with the
early agricultural civilizations of
Mesopotamia3. The vibrant poppy
flower is believed to have first been
cultivated along the banks of the
Tigris and Euphrates, where the
Assyrian people devised a method
for extracting the potent sap from
the golf-ball sized pod that emerges

once the flowers drop their petals.
The sap, known as opium, and
its derivative opioids, were used
widely across ancient civilizations:
The Sumerians referred to the plant
using ideograms translating to “joy
plant;” the ancient Indians grew
and consumed it; the Greeks used
potions derived from it; and the
Egyptians created its first known
derivative, Thebaine. The drugs
were widely regarded as a powerful
method by which to escape both
physical and psychic pain, and
these benefits made it easy for
early civilizations to overlook the
clear risk of addiction and lethality
of the drug.
As
medicine
began
to
advance, the opioid molecule was
recast as a miracle cure all. In 1806,
German
physician
apprentice
Friedrich
Serturner
distilled
morphine, named for Morpheus,
the Greek God of sleep3. The drug
was a powerful pain reliever and
significantly more effective than its
parent opium. Its administration
was simplified by the development
of the hypodermic needle in 1853.
The needle allowed for the drug to
be delivered directly into the blood
stream, rather than be absorbed
through the digestive tract, as
was the case for the commonly
used pills and anal suppositories,
ensuring doses were rapidly
and accurately admisitered to
the central nervous system. This
method of administration was
also believed to limit addiction:
since the drugs were not being
consumed, healthcare providers
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for any purpose aside from medical
use, with “exceedingly severe”
penalties for the sale of recreational
narcotics.
This recommendation would
come to fruition with “An act to
prohibit the importation and use
of opium for other than medical”,
approved in February of 1909,
which prohibited the possession,
distribution, or sale of opium for
any purpose aside from medical
use.5 This was soon followed by
the Harrison Narcotics Tax Act of
1914, which, at face value, aimed
to regulate the sale of opium and
tax those distributing narcotics
for medical use, but was used in
practice to enforce a prohibition on
the use of narcotics for most medical
conditions and the prescription of
maintenance opioids to addicted
clients, whose ailment was not yet
considered medical.6,7 Those in
violation of the act could face up to
$2,000 in fines, the equivalent of a
whopping $51,074 in modern U.S.
dollars, and up to 5 years in prison.
The enactment of these
legislative acts ushered in an
era of fear surrounding the
consumption and prescription of
opioids, coined opiophobia, and
severe pain went untreated for
decades. Even the terminally ill
were denied the dignity of a pain
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free death, as doctors feared the
ramifications of prescribing opioids
and obtaining even small amounts
required signatures from multiple
practitioners. During this time,
concoctions combining multiple
drugs for their synergistic effects,
such as the Brompton Cocktail an elixir consisting of high proof
alcohol,
morphine,
cocaine,
antipsychotic
sedatives,
and
chloroform water - were used to
treat pain in the absence of access
to more potent opioid painkillers.3,8
It wouldn’t be until the 1970s
that opinions on opioids would
begin to change, prompted
primarily by healthcare providers
and advocates closely involved
with cancer patients. In a 1973
article published in the Annals
of Internal Medicine, American
doctors Richard Marks and Edward
Sachar highlighted a serious
problem of undertreatment with
narcotics leading to needless
suffering in medical inpatients9.
The pair reported two key findings:
1) over 70% of the patients
interviewed reported moderate
to severe distress despite opioid
treatment, and 2) the treating
physicians possessed considerable
misinformation relating to opioid
painkillers. More often than
not, physicians underestimated

effective doses, and overestimated
both the time of action and risk of
addiction related to the amount
of opioid painkillers used in
treatment, leading to egregious
undertreatment of pain, sometimes
in the case of terminal cancer.
This article was a call for action,
reinvigorating
the
discussion
surrounding the use of the most
powerful painkillers at humankind’s
disposal, and began the process
of rescuing opioids from their long
vilification.
Across the pond, Cicely
Saunders, a nurse, researcher,
and founder of St. Christophers
Hospice in London, began to treat
terminally ill cancer patients with
opioids and gather clinical data
regarding their efficacy3. According
to Robert Twycross, a researcher
at St. Christophers, by 1975, the
vast majority of the 500 patients
to pass through St.Christopher’s
doors that year were treated with
diamorphine, better known as
heroin 10. The patients were treated
on a preemptive 4-hour cycle,
totaling 5 doses per day, which
aimed to address pain before it had
a chance to arise. Of the patients
receiving opioid therapy, most
were maintained on doses of less
than 10 mg and only 8% received
doses exceeding 30 mg. None of
these patients were believed to
have become addicted, as they did
not demonstrate an overpowering
urge to take the drugs for their
psychological effects. Further, the
high daily doses did not appear to
the researchers to be an obstacle
to daily functioning or mobility,
laying to rest concerns about
patients suffering from a “living
death”, drugged and unable to
move in their last moments, which
was a serious concern of the time.
Ultimately, Saunders and Twycross
highlighted that for the terminally ill,
who averaged only 16 days at their
center, the threat of addiction was
negligible, and thus the benefits of
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opioid use far outweighed the risk.
The pair believed people deserve
to spend their last days pain free
and die a humane, dignified death,
even if it meant the use of strong
opioids.

A Major
Breakthrough
For centuries, opioids, a class
of chemical compounds derived
from the opium poppy, were
considered drugs that by some
divine benevolence or coincidence
relieved pain and produced
euphoria in those who consumed
it. However, 1973 ushered in a
new era in the understanding of
the pain relieving and addictive
properties of opioids, and the pain
experience. Candace Pert and
Solomon Snyder, researchers at
Johns Hopkins School of Medicine,
were the first to successfully
identify opioid receptor sites,
providing groundbreaking insight
into the mechanisms through which
opioids achieved their effects and
solidifying them as an “intrinsic and
essential” component of the pain
system 11,12. Continued research
revealed the system was comprised
of three receptor types - delta,
kappa, and mu - which were acted
upon not only by opioids obtained
from the external environment, but
also proteins produced internally11.
The newly discovered system was
branded the endogenous (meaning
internal) opioid system, after the
external compounds that act upon
it.
Of particular interest to our
story is the μ receptor, named
for its high affinity with the
opioid morphine 11. An internally
manufactured class of endogenous
proteins naturally bind to and excite
μ-receptors with great affinity:
endomorphins. These proteins
play a major role in the perception
of pain and reward processes. In
this way, the endogenous opioid

system explains the inextricable
link between two fundamental
drivers of human behavior: pain
and pleasure 13. At an evolutionary
level, these elements are critical for
the survival of a species. Pleasure is
experienced as an innate biological
reward for performing behaviors
that have the potential to promote
the health and species well-being,
such as eating or procreating.
Conversely, pain is experienced
in response to harmful stimuli and
plays an important adaptive role
by promoting the avoidance of the
stimuli and encouraging behaviors
that achieve relief should pain be
incurred.
Pain is now understood to
be a multidimensional experience
comprising a sensory component
that determines the physical
quality and intensity of a stimuli,
and an affective dimension that
determines how unpleasant we

rate stimuli 14. If your affective
dimension were to disappear,
and someone poked you with a
sharp stick you would register the
pressure of the poke, and perhaps
the sharp quality, but would not
necessarily rate the experience
as unpleasant or painful. This is
essentially how opioids induce pain
relief. The anterior cingulate cortex
(ACC), is a brain region dense in
μ-receptors and essential for pain
relief 15. When pain is incurred the
region releases the endomorphins
which bind to the μ-receptors and
quiet the brain activity caused
by your injury. Opioids resemble
these compounds, but their more
compact structure allows them
to overwhelm the μ receptor,
producing
more
pronounced
pain relief than the internally
manufactured compounds3. The
painkillers work, not by addressing
the physical ailment responsible for

The Progression Cancer Pain Treatment as Instructed by the WHO’s Cancer Pain Ladder for Adults18.
Original image by Lindsay Spitz
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the pain, but rather by blunting our
affective evaluation of experience.
μ-receptors
are
also
prominently
located
in
the
“reward” system, a collection of
regions situated deep in the brain
12,16
. When an action is performed
that is good for the organism
the activation of the μ-receptors
produces pleasurable feelings
that encourage repetition of the
behavior13. This system is the
reason high calorie foods are so
tasty and hugging a loved one
makes you feel warm and fuzzy. This
is also the system that goes awry
in addiction, which is at its core
disordered reward12,16. Addiction
was not a moral failing, rather it is
an irreversible neurological disease.
Today it is common knowledge
that chronic use of opioids leads
to a gradual inability to experience
their benefits, but at the time of our
story these realities were just being
discovered. The euphoria and pain
relief associated with the drug
diminish the longer the drug is
consumed until, eventually the user
must take the drug, not as a means
to experience pleasure, but in order
to avoid the unpleasant effects of
withdrawal. Unfortunately, at the
time of the budding revolution of
pain management the system that
dictates these effects had only
just been discovered. Healthcare
practitioners possessed only a
rudimentary understanding of this
complex process, which allowed
them to forge ahead under well
intentioned but misguided notions
related to the use of opioids in the
treatment of pain.

The Dawn of the
American Opioid
Crisis
The American Opioid Crisis
began with the best of intentions.
Jan Stjernsward, an oncologist
and chief of the World Health
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Organization’s
(WHO)
cancer
program beginning in 1980,
also believed, like Saunders and
Twycross, that opioids had a
place in the treatment of cancerrelated pain. In 1986, under his
guidance the WHO released
a comprehensive manual for
cancer pain management17. In
this document, the WHO made
its message clear: freedom from
pain, especially in the case of the
terminally ill, was a universal human
right and should be treated as such.
The manual noted that doctors
must consider all the elements biological, psychological, social,
and sociocultural - that contribute
to a patient’s total pain, not just
the physical malady. Healthcare
providers were also advised to
“believe the patient’s complaint of
pain,” and treat them accordingly.
With this, the WHO provided
an “analgesic ladder” detailing
a standardized escalation of
drug therapy in cancer pain
management18.
Let’s say you approach a
doctor with complaints of pain
related to a cancerous tumor in
your chest. According to the WHO
ladder, your physician would likely
begin by prescribing you aspirin
or nonsteroidal anti-inflammatory
drugs (NSAIDs) in the case of mild
pain; the kinds of drugs average
Joes take for their various aches
and pains. An adjuvant may also be
prescribed at this time to slow tumor
growth. If the non-opioid treatment
was ineffective in controlling your
pain or it escalated to a moderate
level during your treatment
process, you would graduate to a
weak opioid medication. These are
drugs like codeine, which you may
have been prescribed following
wisdom teeth removal or similarly
mild surgeries. This treatment
could also be combined with
the aforementioned non-opioid
painkillers for additional pain
relief, as the non-opioid painkillers

operate on different systems than
the opioid medication. Now let’s
say your tumor infiltrated your
lung, further escalating the severity
of your pain. At this point your
physician would be prompted to
prescribe a strong opioid, with
morphine highlighted as the drug
of choice, with or without the
additional drug therapies.
The implementation of the
WHO analgesic ladder was met with
great success. In a retrospective
analysis of the method conducted
by the WHO Collaborating Cancer
Center at The National Cancer
Institute of Milan, correct use of the
ladder was found to reduce pain
to ⅓ of its initial intensity and was
effective in over 70% of patients,
ultimately sparing them from
invasive pain control surgeries19.
These patients reported no major
changes in functioning and the time
spent sleeping doubled. Additional
retrospective analysis indicated
comparable
positive
results,
and noted none of their cohort
developed an addiction to strong
opioids20. These analyses supported
the “regular and sufficient” use of
Old botlle of opioid pain killer
By Science Museum, London
From Welcome Collection (CC BY 4.0)
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opioids as instructed by the WHO
analgesic ladder and lauded it as
the “most suitable treatment” for
the palliative care of advanced
cancer patients. The introduction
of this policy, and its subsequent
success, marked a major turning
point in the American discussion on
opioids; with the understanding of
pain relief as a human right and the
success of opioid therapies in the
management of cancer pain, the
powerful compounds once again
entered the limelight.
The success of the WHO
ladder in treating cancer pain and
the limited reports of addiction
and/or impaired functioning, led
the medical field to contemplate
the undertreatment of other
chronic pain conditions, and
ponder whether the use of opioid
therapies could be extended
beyond cancer-related pain to
other chronic conditions. However,
the majority of these concerns
were expressed by individuals
who had been closely involved
in the research and treatment
of cancer-related pain, and had
largely ignored the developing
understanding of chronic pain not
resulting from direct tissue damage
as a complex issue incorporating
biological, psychological and social
dimensions in a manner distinct
from chronic pain secondary to a
condition such as cancer 12,21.
Additionally,
while
the
discussion of the use of opioids
progressed rapidly over the 1970s
and 80s there had been little in the
way of rigorous assessment of their
efficacy in non-malignant chronic
pain conditions. The commonly
held belief that the therapeutic
use of opioids in the treatment of
non-cancerous chronic pain rarely
resulted in addiction did not reflect
the findings of controlled safety
studies. Rather, the conclusion
was drawn from two retrospective
studies from the era, which lacked
rigorous experimental designs,

but were nevertheless utilized by
physicians and aggressive drug
marketing to support the safety and
efficacy of opioids and promote
the expansion of opioid therapy to
treat non-cancerous chronic pain.
The first of the two, a short
paragraph published in the New
England Journal of Medicine
in 1980, retroactively assessed
the rates of addiction observed
in patients who had received at
least one opioid painkiller during
inpatient care between 1970 and
197922. It stated that of those who
received the opioid therapy, only
4 became addicted. Beyond the
numbers, there is no indication
as to the cases, for how long, or
in what quantities these drugs
were used to treat. Additionally,
all were inpatients, meaning the
consumption of narcotics were
regulated by healthcare providers;
providers
who
presumably
undertreated pain in a manner
akin to the physicians described by
Marks and Sachar in 1973.
The second, published by
doctors Richard Portenoy and
Kathleen Foley in 1986, both
early advocates of the expansion
of opioid therapies, provided an
analysis of 38 patients maintained
on opioids for pain unrelated to
cancer 23. Of these individuals only
two, both of whom had a history
of substance abuse, misused the
drugs which provided adequate
relief in about 63% of patients. The
paper asserts that bad brains, not
bad drugs, led to addiction. As
long as doctors obtained adequate
patient histories, addiction to
painkillers could be avoided.
However, so little was understood
about addiction and what elements
presented an increased risk that
doctors were left to make the call
as to whether their patients were at
risk with little to no guidance.
The prescription of opioids
would rise steadily both in number
and dose over the ensuing

decades aided in part by programs
introduced to answer the lingering
concerns about the undertreatment
of pain. In 1995, the American Pain
Society introduced their “Pain: The
fifth vital sign” campaign which
operated under the logic that pain
if assessed with the same regularity
and standardization as the other
vital signs - pulse, blood pressure,
temperature, and respiration - it
would have a better chance of
being treated properly 3,24. In the
years following, The Veteran’s
Health Administration and The Joint
Commission for the Association
of
Healthcare
Organizations,
regulatory bodies that together
influenced the majority of the
American
healthcare
system,
adopted the policy, and oversight
agencies including The Medical
Board and FDA relaxed their
scrutiny of opioid prescribing24.
The swift implementation of
standardized pain management
policy led to heavy reliance on
opioid painkillers, and the idea that
pain counteracted the euphoric
and sedative qualities of the drugs
meant there was no ceiling on the
amount of opioids prescribed. As a
result, over the following 15 years,
there has been a “proportionate
quadrupling in opioid sales and
mortality” rates 3,24. Per capita
opioid
prescription
peaked
between 2010 and 2012, when
81 of every 100 individuals were
prescribed an opioid painkiller.
2012 was the height of opioid
consumption; in a single year
Americans consumed 165,525 kg
of opioids compared to 46,946 kg
consumed in 2000 24. Fortunately,
steps taken to regulate and monitor
the sale of prescription opioids and
improved education surrounding
the use of opioid painkillers have
helped to contain the epidemic
3,24
. 2018 was the first year to see a
decline in opioid overdose deaths
since 1990, dropping by 5.1% from
the previous year.21,25
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